Aviva has agreed to divest its entire 49% shareholding in its Taiwanese joint venture First Aviva Life (Aviva Taiwan) to its partner First Financial Holding (FFH).

The move by the British insurance behemoth  comes in the wake of a strategic review, which revealed that Taiwan is a less profitable market for the company and hence no longer central to the group’s strategy.

“Following a strategic review of Aviva Taiwan, Aviva concluded that the business is not central to the group’s strategy to focus on markets where it can achieve scale and profitability or have a distinct competitive advantage,” Aviva said in a statement.

The sale of the Taiwan business will have no tangible impact on Aviva’s IFRS net assets, Solvency II capital position and IFRS operating profit.

Aviva Asia executive chairman and Aviva Digital global chairman Chris Wei said: “We have refocused Aviva’s Asian business on core markets where we have excellent opportunities to grow.

“With our strong partners and our digital focus, we are intent on disrupting the traditional insurance market.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Subject to customary closing conditions, the transaction is pending receipt of regulatory approval and is expected to conclude in 2018.